Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

SRZN - Surrozen, Inc. So'nggi Yangiliklar | Finranks

Home

SRZN

S

Surrozen, Inc. (SRZN)

NCM – Real vaqt narxi. Valyuta: USD

28.90

+0.90 (3.21%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

28.88

-0.02 (-0.07%)

Bozordan keyin: Mar 27, 2026, 6:50 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the fourth quarter and full year 2025 and provided a business update.

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen to Present at Upcoming Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences.

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P.

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.

Videolar

No Data

There is no data to display

Press-relizlar

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the fourth quarter and full year 2025 and provided a business update.

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P.

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.